Becton Dickinson gearing up for ProbeTec TB gene amplification test clinicals.
This article was originally published in The Gray Sheet
Executive SummaryBECTON DICKINSON'S PROBETEC TB GENE AMPLIFICATION TEST will enter clinical trials "shortly" in the U.S. and overseas, the firm says. Trials of the ProbeTec system for testing for tuberculosis likely will include data from 4,000 to 5,000 samples, the company says. ProbeTec is based on BD's strand displacement amplification (SDA) technology.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.